1. Home
  2. MBAI vs GTBP Comparison

MBAI vs GTBP Comparison

Compare MBAI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.65

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.47

Market Cap

12.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
GTBP
Founded
2004
1965
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
12.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
MBAI
GTBP
Price
$1.65
$0.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
49.9K
662.3K
Earning Date
05-08-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.39
52 Week High
$3.92
$3.73

Technical Indicators

Market Signals
Indicator
MBAI
GTBP
Relative Strength Index (RSI) 49.18 49.60
Support Level $1.38 $0.40
Resistance Level $1.89 $0.59
Average True Range (ATR) 0.14 0.03
MACD -0.01 0.01
Stochastic Oscillator 30.77 79.55

Price Performance

Historical Comparison
MBAI
GTBP

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: